Who Paid My Doc
Ashwin Shah
Urology Monroe, MI Medical Doctor
NPI 1710983812 CMS profile 305219
730 N MacOmb St, Ste 319, Monroe, MI 48162
General payments
$19,026
Research payments
$0
Ownership & investment interest
$35,800
Through program year 2024, Ashwin Shah of Monroe, MI is reported in the CMS Open Payments database as having received $19,026 across 142 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $35,800 across 9 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 89th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $829 | 2 | |
| 2023 | General | $22 | 1 | |
| 2022 | General | $2,057 | 41 | |
| 2021 | General | $2,302 | 32 | |
| 2020 | General | $4,468 | 24 | |
| 2019 | General | $9,349 | 42 | |
| 2024 | Ownership | $1,600 | 1 | |
| 2023 | Ownership | $3,000 | 1 | |
| 2022 | Ownership | $2,700 | 1 | |
| 2021 | Ownership | $3,500 | 2 | |
| 2020 | Ownership | $8,000 | 2 | |
| 2019 | Ownership | $17,000 | 2 |
Beside peers
- Ashwin Shah
- Urology median
- Middle half of Urology
- National median
In program year 2025, general payments to Ashwin Shah were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.
Show as a table
| Year | Ashwin Shah | Urology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $9,349 | $480 | $147–$1,201 | $163 |
| 2020 | $4,468 | $246 | $87–$645 | $114 |
| 2021 | $2,302 | $358 | $111–$1,000 | $132 |
| 2022 | $2,057 | $476 | $143–$1,263 | $149 |
| 2023 | $22 | $560 | $168–$1,461 | $160 |
| 2024 | $829 | $563 | $170–$1,464 | $164 |
| 2025 | $0 | $629 | $190–$1,620 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 18 billing codesPaid by Medicare
$42,929
Medicare patients
132
Services billed
650
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 53% | |
| Chronic kidney disease | 52% | |
| Ischemic heart disease | 50% | |
| Heart failure | 43% | |
| Diabetes | 40% | |
| COPD | 36% | |
| Atrial fibrillation | 35% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
142 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urology in Michigan
Related records
Urology in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Urology
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.